Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 2/3 1Phase 1 1

Status

Completed 15Recruiting 6Withdrawn 4Terminated 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 2Lymphoid 2Other solid neoplasm 1

Conditions

Cytokine Release Syndrome 2Schwannomatosis 1Pain 1Neurilemmoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Chronic Pain 1Burkitt Lymphoma 1Advanced Malignant Solid Neoplasm 1

Interventions

pembrolizumab 551Specimen Handling 465Carboplatin 441Magnetic Resonance Spectroscopy 430Cyclophosphamide 412Cisplatin 397Radiotherapy 313Gemcitabine 309Bevacizumab 307Paclitaxel 294Biopsy 261Drug Therapy 249Capecitabine 242Oxaliplatin 239fludarabine 237Nivolumab 224venetoclax 219Injections 213Docetaxel 205Fluorouracil 203Dexamethasone 187Radiosurgery 172Rituximab 158Pemetrexed 153Standard of Care 146durvalumab 143Leucovorin 139atezolizumab 138toripalimab 134tislelizumab 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Recruiting × Interventional × siltuximab × Clear all
NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT06679829 2026-04-24

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
215 enrolled
Plasma cell

Multiple Myeloma

NCT05684692 2026-04-23

Screening Trial for Pain Relief in Schwannomatosis (STARFISH)

Massachusetts General Hospital

Phase 2 Recruiting
40 enrolled

Schwannomatosis, Neurilemmoma, Pain, Chronic Pain

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
40 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
20 enrolled
Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06447376 2025-05-11

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

Case Comprehensive Cancer Center

Phase 1 Recruiting
20 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡